SG Americas Securities LLC Raises Position in Replimune Group, Inc. $REPL

SG Americas Securities LLC increased its stake in Replimune Group, Inc. (NASDAQ:REPL) by 110.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 151,674 shares of the company’s stock after purchasing an additional 79,719 shares during the quarter. SG Americas Securities LLC owned approximately 0.18% of Replimune Group worth $1,160,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Braidwell LP increased its position in Replimune Group by 550.3% in the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after buying an additional 2,327,205 shares during the last quarter. Balyasny Asset Management L.P. lifted its position in shares of Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after buying an additional 2,195,448 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of Replimune Group during the 4th quarter worth $17,568,000. Commodore Capital LP bought a new position in shares of Replimune Group during the 4th quarter worth $13,851,000. Finally, JPMorgan Chase & Co. increased its holdings in Replimune Group by 2,333.6% in the 4th quarter. JPMorgan Chase & Co. now owns 925,173 shares of the company’s stock worth $8,993,000 after acquiring an additional 887,157 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Weiss Ratings cut Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Wedbush lifted their target price on shares of Replimune Group from $6.00 to $9.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 30th. HC Wainwright reissued a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. Finally, Cantor Fitzgerald cut shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Two equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.12.

Insider Activity at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the transaction, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Replimune Group Stock Performance

NASDAQ REPL opened at $11.58 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The company has a fifty day moving average of $7.16 and a 200-day moving average of $7.35. Replimune Group, Inc. has a 52-week low of $1.50 and a 52-week high of $13.24. The company has a market capitalization of $972.03 million, a P/E ratio of -3.43 and a beta of 0.86.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities research analysts predict that Replimune Group, Inc. will post -2.25 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.